Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide

Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma

(2014) Ayca Ersen et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma

(2014) Luis Syro et al.   Hormones-International Journal of Endocrinology and Metabolism

Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy

(2014) Olga Moshkin et al.   Hormones-International Journal of Endocrinology and Metabolism

Aggressive Silent GH Pituitary Tumor Resistant to Multiple Treatments, Including Temozolomide

(2013) Marie Batisse et al.   CANCER INVESTIGATION

DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors

(2013) Toshio Hirohata et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges

(2013) Gazanfar Rahmathulla et al.   OncoTargets and Therapy

Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment

(2012) Melanie Philippon et al.   ANNALES D ENDOCRINOLOGIE

Temozolomide in the management of dopamine agonist-resistant prolactinomas

(2012) B. C. Whitelaw et al.   CLINICAL ENDOCRINOLOGY

Temozolomide in aggressive pituitary adenomas and carcinomas

(2012) LD Ortiz et al.   Clinics

Pituitary carcinoma recurrent to the lumbar intradural extramedullary space: Case report

(2012) Paul M. Arnold et al.   JOURNAL OF SPINAL CORD MEDICINE

Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management

(2012) Ilyess Zemmoura et al.   Pituitary

Functional molecular morphology of anterior pituitary cells, from hormone production to intracellular transport and secretion

(2011) Akira Matsuno et al.   Medical Molecular Morphology

A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report

(2011) Mineko Murakami et al.   NEUROSURGERY

New targeted therapies in pituitary carcinoma resistant to temozolomide

(2011) Emmanuel Jouanneau et al.   Pituitary

Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature

(2011) A. K. Annamalai et al.   Pituitary

Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review

(2011) Lorenzo Curtò et al.   TheScientificWorldJOURNAL

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

(2010) Marco Losa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases

(2010) H. Bode et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

(2010) Zachary M. Bush et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

(2010) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly

(2010) Emilie Morin et al.   Pituitary

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy

(2010) Troy H. Dillard et al.   Pituitary

O6-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas

(2009) Georg Widhalm et al.   CANCER

High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease

(2009) Akira Takeshita et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

(2009) C Hagen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A novel use of temozolomide in a patient with malignant prolactinoma

(2009) Stephen Byrne et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Usefulness of composite methionine–positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma

(2009) Hidetoshi Ikeda et al.   JOURNAL OF NEUROSURGERY

USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS

(2009) Safraz Mohammed et al.   NEUROSURGERY

Possible role of a radiation-induced p53 mutation in a Nelson’s syndrome patient with a fatal outcome

(2009) Emilia Modolo Pinto et al.   Pituitary

P53gene mutation in an atypical corticotroph adenoma with Cushing's disease

(2008) Sachiko-Tsukamoto Kawashima et al.   CLINICAL ENDOCRINOLOGY

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

(2008) Ann I. McCormack et al.   CLINICAL ENDOCRINOLOGY

Treatment of Nelson's syndrome with temozolomide

(2008) V J Moyes et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Pituitary Carcinoma Presenting with Multiple Metastases: Case Report

(2008) Aslan Guzel et al.   JOURNAL OF CHILD NEUROLOGY